IGF-1 LR3 1 mg

IGF-1 LR3 1 mg contains an engineered IGF-1 analog used in research settings as a cell culture supplement and for studying IGF-1 receptor signaling. In non-medical bodybuilding contexts, it is commonly referenced for its direct IGF-1 receptor activity, though such use falls outside approved indications.

Because of its extended half-life of approximately 20–30 hours, IGF-1 LR3 is typically referenced as being administered once daily. Community protocols commonly reference doses of 20–80 mcg per day, with cycle lengths limited to 4–6 weeks due to receptor downregulation concerns.

IGF-1 LR3 does not suppress endogenous testosterone production because it acts on the IGF-1 receptor rather than the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is therefore generally not considered necessary after IGF-1 LR3 use alone. A break of at least 4 weeks is commonly referenced to allow receptor resensitization.

IGF-1 LR3 activates the IGF-1 receptor with high affinity, driving cell proliferation, differentiation, and protein synthesis through PI3K/AKT and MAPK signaling pathways. Its reduced binding to IGF-binding proteins keeps more peptide in the active free form and extends its half-life compared to native IGF-1.

IGF-1 LR3 has an extended half-life of 20–30 hours, meaning a single dose provides sustained receptor activation over that period. Effects on downstream signaling begin shortly after administration, but cumulative effects on recovery or physique would develop over days to weeks of consistent use.

There is no single growth factor peptide that is universally best. IGF-1 LR3 provides direct IGF-1 receptor activation with an extended half-life, while Dragontropin HGH acts upstream on the GH-IGF-1 axis and GH secretagogues like Ipamorelin stimulate endogenous GH release. The appropriate choice depends on individual goals and risk tolerance.

IGF-1 LR3 is an engineered analog with an arginine substitution at position 3 and a 13-amino acid N-terminal extension that reduces its binding to IGF-binding proteins by over 100-fold. This modification extends its half-life to 20–30 hours compared to 12–15 hours for native IGF-1 and increases its potency in cell culture and animal models.

IGF-1 LR3 is a modified IGF-1 analog that activates the IGF-1 receptor for sustained growth signaling. MGF (Mechano Growth Factor) is a different splice variant of the IGF-1 gene that acts primarily through IGF-1R-independent mechanisms to activate satellite cells. MGF has an extremely short half-life of minutes, while IGF-1 LR3 circulates for hours.

20 mcg is commonly referenced as a conservative starting dose for IGF-1 LR3 in community protocols. Research-context protocols reference ranges of 20–40 mcg per day for conservative use and up to 120 mcg per day in advanced short blocks. The 1 mg vial contains 1,000 mcg total, providing 25–50 doses at these levels.

IGF-1 LR3 1 mg is labeled at 1 mg of IGF-1 LR3 per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

Yes. A published laboratory report dated January 19, 2024 measured IGF-1 LR3 1 mg at 1.05 mg, equivalent to 105% of its 1 mg label claim.

The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.

Lyophilized IGF-1 LR3 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or 0.6% acetic acid. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.